Drug, bio-affecting and body treating compositions inventions 05/07

20070123448 - Novel chemical entities affecting neuroblastoma tumor-initiating cells: Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children... Agent: Jagtiani + Guttag

20070123449 - High load particles for inhalation having rapid release properties: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a... Agent: Elmore Patent Law Group, PC

20070123450 - Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells: The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized glutathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can... Agent: Wolf Greenfield & Sacks, P.C.

20070123451 - Use of adiponectin to diagnose and treat malignancy: Methods aiding in the diagnosis of endometrial cancer or a risk of endometrial cancer are disclosed, in which the level of adiponectin is assessed in a test sample. Methods aiding in the diagnosis of an epithelial cancer or a risk of an epithelial cancer are also disclosed, in which the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070123452 - Method of selecting novel immunosuppressant: The present invention provides a method of selecting an IL-2 production inhibitor and/or an immunocyte proliferation inhibitor having low GATA-1 production inhibitory activity, which comprises measuring the HDAC4 and/or HDAC8 inhibitory activity of a test substance, and a method of selecting an immunosuppressant having low thrombocytopenic activity, which comprises measuring... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070123454 - Peptide anti-tumor agent: Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.... Agent: Darby & Darby P.C.

20070123453 - Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion: The present invention provides a method of inducing weight loss in a patient, comprising continuous infusion of an effective amount of an MC4R agonist peptide into the patient. Additionally, the present invention provides a method of treating obesity in a patient, comprising continuous infusion of an effective amount of an... Agent: Eli Lilly & Company

20070123457 - Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof: A chimeric carrier protein having a multimerization domain and at least one drug attached thereto via a spacer is disclosed. The protein may be targeted by associating at least one amino acid sequence having an amino acid domain targeted to a specific site of action. In a further embodiment of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070123458 - Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions: Contortrostatin, a homodimeric disintegrin, modulates the adhesion, motility, and invasiveness of integrin expressing tumor cells. When formulated as a pharmaceutically acceptable composition, the proteins can be used to treat patients by inhibiting or disrupting disease processes associated with an integrin binding to an αvβ3 or αvβ5 integrin.... Agent: Foley & Lardner LLP

20070123462 - Effects of tissue transglutaminase on beta-amyloid-induced apoptosis: The present invention relates to a method of inhibiting beta-amyloid-induced death of neuronal cells in a subject by inhibiting human tissue transglutaminase in the subject under conditions effective to inhibit beta-amyloid-induced death of neuronal cells. Also disclosed are methods for identifying candidate compounds suitable for inhibiting beta-amyloid-induced death of neuronal... Agent: Nixon Peabody LLP - Patent Group

20070123459 - Il-17 like molecules and uses thereof: Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof.... Agent: Marshall, Gerstein & Borun LLP

20070123455 - Immunomodulatory agents for treatment of inflammatory diseases: The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and/or S100A9 for reducing inflammation.... Agent: Medlen & Carroll

20070123463 - Methods and compositions for modulating carbohydrate metabolism: Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake... Agent: Bozicevic, Field & Francis LLP

20070123464 - Methods and reagents for treating inflammation and fibrosis: Methods are provided for providing anti-inflammatory activity and inhibiting a fibrotic disease, such as pulmonary fibrosis, in an individual. The methods comprise administering a biologically effective amount of latency-associated peptide (LAP) to the individual. Also provided are pharmaceutical compositions comprising LAP for use in accordance with these methods.... Agent: Calfee Halter & Griswold, LLP

20070123456 - Novel regulator of endothelial cell function and vessel remodeling: The present invention relates to previously unknown biological roles of Nogo-B. We have discovered that Nogo-B is a component of endothelial cells. We have also discovered that Nogo-B is highly expressed in intact blood vessels. The amino terminus of Nogo-B promotes the adhesion, spreading and migration of endothelial cells and... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070123465 - Oligomeric peptides and their use for the treatment of hiv infections: e

20070123460 - Probiotic compounds from lactobacillus gg and uses therefor: The invention provides methods and compositions for the treatment of inflammatory disorders, such as inflammatory bowel diseases (IBDs). The use of bacteria-free, probiotic-derived compounds instead of live bacteria provides a safety advantage over the use of live bacteria. In addition, the administration of isolated compounds will provide more reliable dosing,... Agent: Marshall, Gerstein & Borun LLP

20070123461 - Reproductive management: A method for breeding, especially a method for breeding dairy cattle without use of heat detection prior to insemination.... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070123466 - Method of treating recurrent miscarriages: Described are methods for treating, preventing, or reducing the risk of, miscarriages, especially recurrent miscarriages. The methods comprise administering to a female subject a therapeutic agent that modulates the activity or binding of components of the complement system, together with a pharmaceutically acceptable carrier. For example, the therapeutic agent can... Agent: Darby & Darby P.C.

20070123467 - Amniotic-derived peptide and uses thereof: The present invention relates to the method(s) of synthesis of and the therapeutic and cosmetic applications of biologically active peptides for improving the appearance of skin, for hastening wound healing and for treating and/or preventing the progression of various conditions, injuries and diseases, including but not limited to viral hepatitis... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070123468 - Prodrugs of active agents: Disclosed herein are prodrugs of active agents which contain at least one amine, phenol, carboxylic acid, or thiol functionality. Also disclosed herein are methods of making prodrugs of active agents, pharmaceutical compositions of prodrugs of active agents and methods of using prodrugs of active agents and pharmaceutical compositions.... Agent: Morgan, Lewis & Bockius, LLP

20070123469 - N- or c- terminally modified small peptides: N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular small peptides that possess improved pharmacokinetic properties such as having a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P450 oxidase. The invention further relates to uses of said compounds in the preparation... Agent: Clark & Elbing LLP

20070123470 - Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue: The present invention is directed to methods for increasing levels of endogenous growth hormone in a mammal by the administration of a combination of a dipeptidyl peptidase IV (DP-IV) inhibitor and a growth hormone secretagogue.... Agent: Merck And Co., Inc

20070123471 - Derivative of glucose and of vitamin f, compositions comprising it, uses and preparation process: An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for... Agent: Thomas L. Irving Finnegan, Henderson, Farabow,

20070123472 - Filtering predictive data: An apparatus, device, methods, computer program product, and system are described that access at least one dataset, based on at least one treatment parameter and at least one predictive basis, determine a graphical illustration of a first possible outcome of a use of the at least one treatment parameter with... Agent: Searete LLC Clarence T. Tegreene

20070123473 - Glycosylated steroid derivatives with anti-migratory activity: Glycosylated steroid compounds having anti-migratory activity and methods for their preparation are disclosed. Pharmaceutical compositions having an effective amount of the glycosylated steroid compounds are also disclosed. The glycosylated steroid compounds may be used as a medicament. Preparation of medicaments containing the glycosylated steroid compounds for treatment of diseases associated... Agent: Knobbe Martens Olson & Bear LLP

20070123474 - Novel loganin analogues and a process for the preparation thereof: The present invention provides novel loganin analogues and a process for the preparation thereof. The present invention further provides the use of Iridoid glycoside loganin isolated from the fruit pulp of Strychnos nux-vomica and its bioactive semi-synthetic analogues against various human cancer cell lines grown in-vitro.... Agent: Cooper & Dunham, LLP

20070123475 - Water-soluble etoposide analogs and methods of use thereof: Etoposide analogs with improved water-solubility such as 4′-O-Demethyl-4′-(N′,N′-dimethyl-glycyl)-4β-(4″-nitroanilino)-4-desoxy-podophyllotoxin (8) and 4′-O-Demethyl-4′-(N′,N′-dimethyl-glycyl)-4β-(4″-fluoroanilino)-4-desoxy-podophyllotoxin (9) are described, along with pharmaceutical formulations containing the same, methods of use thereof, and intermediates and methods of making the same.... Agent: Myers Bigel Sibley & Sajovec

20070123477 - Compositions comprising amphotericin b, methods, and systems: The present invention comprises compositions and formulations comprising amphotericin B, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of... Agent: Nektar Therapeutics

20070123476 - Polyene antibiotic for controlling fungal growth in banana crops: The present invention relates to a process to treat banana plants against disease wherein a polyene antibiotic is applied on the plant. In particular a process is described to protect banana crops from the devastating Sigatoka and Panama diseases. To that effect, banana plants are treated with a preparation comprising... Agent: Nixon & Vanderhye, PC

20070123478 - Compositions useful for reducing nephrotoxicity and methods of use thereof: The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted oligosaccharide, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the oligosaccharide is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.... Agent: Greenberg Traurig, LLP

20070123481 - Antisense iap oligonucleotides and uses thereof: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070123482 - Chemically modified oligonucleotides for use in modulating micro rna and uses thereof: This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides.... Agent: Fish & Richardson PC

20070123486 - Composition for coordinated vegf and pdgf expression, and methods of use: Compositions for co-expression of VEGF and PDGF at a desired ratio, and their methods of use, are provided.... Agent: Bozicevic, Field & Francis LLP

20070123484 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified... Agent: Woodcock Washburn LLP

20070123483 - Method and composition for treating obesity by targeting cathespin: Methods and compositions are provided for modulating fat storage of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that fat storage by... Agent: Wilson Sonsini Goodrich & Rosati

20070123487 - Methods and compositions for treating prostate cancer using dna vaccines: A DNA vaccine for the treatment of prostate cancer, comprising a plasmid vector comprising a nucleotide sequence encoding prostatic acid phosphatase (PAP) operably linked to a transcription regulatory element, wherein upon administration to a mammal a cytotoxic immune reaction against cells expressing PAP is induced. In preferred embodiment, the PAP... Agent: Quarles & Brady LLP

20070123480 - Oligonucleotides targeting prion diseases: Randomer phosphorothioate oligonucleotide compositions have been described that inhibit PrPc conversion to PrPcs with a high level of potency. Pharmaceutical compositions or kits containing such compounds, and methods of using such compounds in the treatment, control, or prevention of prion diseases are also described.... Agent: Birch Stewart Kolasch & Birch

20070123479 - Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders: The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged,... Agent: Foley And Lardner LLP Suite 500

20070123485 - Universal target sequences for sirna gene silencing: The present invention provides methods for designing a sequence for efficient short interference RNA molecules. In particular, the present invention defines a universal target for siRNA derived from the consensus sequence of the polyadenylation signal in conjunction with unique sequences for gene silencing and inhibition of viral replication in a... Agent: Winston & Strawn LLP Patent Department

20070123489 - Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome: A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD... Agent: Alston & Bird LLP

20070123488 - Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis: The invention relates to pharmaceutical compositions for the treatment of multiple sclerosis which comprises a zinc-hyaluronan complex, preferably a zinc-hyaluronan complex with a molecular weight of 800-1200 kDa, as active ingredient and a pharmaceutically acceptable carrier and/or additive. The process for the preparation of said pharmaceutical compositions as well as... Agent: The Firm Of Karl F Ross

20070123490 - Preventing or reducing oxidative stress or oxidative cell injury: A water-soluble cellulose derivative is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for regulating Stearoyl-CoA Desaturase-1 gene expression and/or ATPF1 gene expression in non-adipose tissues of the animal.... Agent: The Dow Chemical Company

20070123491 - Podophyllotoxin derivatives as igf-1r inhibitors: The invention refers to new compounds, e.g. podophyllotoxin derivatives, as well as to the use thereof and of known compounds as specific inhibitors of the insulin-like growth factor-1 receptor (IGF-1R). Said compounds can be used for treatment of IGF-1/IGF-1R dependent diseases, such as cancer, psoriasis, arteriosclerosis, certain endocrine and metabolic... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070123492 - Analogs of lysophosphatidic acid and methods of making and using thereof: Described herein are analogs of lysophosphatidic acid. Also described herein are methods of making and using analogs of lysophosphatidic acid.... Agent: Needle & Rosenberg, P.C.

20070123493 - Benzamide derivative: where A1 is C—X1 or N; Q1 is —A2═A3—, or a heteroatom selected from —O—, —S—, and —N(R10)—; Q2 is —A4═A5—, or a heteroatom selected from —O—, —S—, and —N(R10)—; provided that Q1 and Q2 are not heteroatoms at the same time; A2 is C—X2 or N, A3 is C—X3... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070123494 - Pyridopyrazine derivatives and their use: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070123495 - Pyrrolo-naphthyl acids and methods for using them: e

20070123496 - Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous system: The present invention relates to the use of aminoguanidine compounds for treating diseases of the nervous system. Aminoguanidine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer's disease, Parkinson's disease, stroke,... Agent: Lahive & Cockfield, LLP

20070123497 - Crystalline solid forms of tigecycline and methods of preparing same: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.... Agent: Wyeth/finnegan Henderson, LLP

20070123498 - Combination of organic compounds: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.... Agent: Novartis Corporate Intellectual Property

20070123499 - Compositions and methods for treatment and prevention of gastrointestinal disorders: The present invention provides compositions and methods for treating and preventing inflammatory bowel disease and other gastrointestinal disorders (e.g., mucositis, radiation induced enteritis, and short bowel syndrome). In particular, the present invention provides methods of treating and preventing symptoms of inflammatory bowel disease and other gastrointestinal disorders using compositions comprising... Agent: Medlen & Carroll, LLP

20070123500 - Prodrugs of erbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds: e

20070123501 - Glutathione peroxidase mimetics and uses thereof: This invention relates to novel organoselenium and tellurium compounds, processes of producing the same and methods of use thereof. The compounds function as mimetics for the catalyst selenoenzyme glutathione peroxidase, which protects cells from oxidative stress.... Agent: Pearl Cohen Zedek Latzer, LLP

20070123502 - Platinum iv complex inhibitor: The invention disclosed herein provides methods for diagnosing and treating diseases and/or conditions associated with dysregulated Stat3-mediated activity.... Agent: Morrison & Foerster LLP

20070123503 - Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases: This invention provides antioxidant cyclic salen-metal compounds, compositions of such antioxidant cyclic salen-metal compounds having superoxide activity, catalase activity and/or peroxidase activity and methods of using such antioxidant cyclic salen-metal compositions to treat or prevent a disease associated with cell or tissue damage produced by free radicals, such as superoxide.... Agent: Bozicevic, Field & Francis LLP

20070123506 - Acid-group-substituted diphenylazetidinones process for their preparation, medicaments comprising these compounds, and their use: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070123504 - Diacylglycerol acyltransferase inhibitors:

20070123505 - Heterocycle-substituted 3-alkyl azetidine derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20070123507 - Process for converting heterocyclic ketones to amido-substituted heterocycles: The present invention provides a safe and convenient process for preparing compounds of Formula (I) from the corresponding heterocyclic ketone.... Agent: Pfizer Inc.

20070123508 - Par2-modulating compounds and their use: This invention relates to compounds, their uses for the elucidation of PAR2 activity and their uses for the treatment or prevention of diseases or disorders related to PAR2 activity, wherein the compound has the general chemical structure:... Agent: Squire, Sanders & Dempsey L.L.P.

20070123509 - Carboxamide derivatives: Novel compounds of the formula (I) in which D, E, Q, T, X, Y, Z, Z′, R1, R4 and R4′ have the meanings indicated in patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment... Agent: Millen, White, Zelano & Branigan, P.C.

20070123510 - Guanidine derivatives: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from... Agent: Dickstein Shapiro LLP

20070123511 - Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer: e

20070123512 - Propionamide derivatives useful as androgen receptor modulators: wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g., in the treatment or prevention of male hypogonadism... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070123513 - Pyridylsulfonamide derivatives: e

20070123514 - Methods of modulating neurotrophin-mediated activity: Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.... Agent: Lahive & Cockfield, LLP

20070123515 - 1,5-substituted indol-2-yl amide derivatives: s

20070123516 - Method of treating mucus hypersecretion: The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070123517 - Pharmacological treatment for sleep apnea: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.... Agent: Marshall, Gerstein & Borun LLP

20070123519 - Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof: The invention relates to compounds having PDE2 inhibitory activities, as well as therapeutic methods by administering said compounds, in particular for treating various diseases of the central or peripheral nervous system. It further deals with pharmaceutical compositions comprising said compounds and methods for preparing said compounds.... Agent: Nixon & Vanderhye, PC

20070123518 - Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations: Said invention is characterised by the application of a small and mini doses of an activated medical substance in the form of an agent for potentiating curing effects, i.e enhancing action of the therapeutic dose of the same medical substance.... Agent: Ilya Zborovsky

20070123520 - Methylene blue therapy of avian influenza: A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to treat or prevent avian influenza virus is described. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine, and thionine. The preferred dye is methylene blue, administered orally... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070123522 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070123521 - Cinnamoyl derivatives and use thereof: The present invention relates to a cinnamoyl compound represented by the formula (I):... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070123523 - Inhibitors of cathepsin s: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively... Agent: Townsend And Townsend And Crew, LLP

20070123524 - N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed... Agent: Merck And Co., Inc

20070123526 - 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives: e

20070123525 - 5-substituted indole-2-carboxamide derivatives:

20070123527 - 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof:

20070123528 - Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity: and pharmaceutically acceptable salts or pro-drugs thereof wherein variable groups are as described herein; which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity are described. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions... Agent: Astrazeneca R&d Boston

20070123529 - Substituted biphenyl compounds: d

20070123531 - 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.... Agent: Foley & Lardner LLP

20070123530 - Azole methylidene cyanide derivatives and their use as protein kinase modulators: s

20070123532 - Piperazine derivatives:

20070123533 - New process for preparing an optically pure 2-morpholinol derivative: The present invention relates to a process for preparing optically pure (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates from a mixture of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and (−)-(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol. The process utilizes continuous chromatography, including techniques like Multi Column Chromatography (MCC), VARICOL, and Cyclojet.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070123534 - Pyrrolotriazine kinase inhibitors: e

20070123535 - 3-amino-1-arylpropyl azaindoles and uses thereof:

20070123536 - Treatment of sexual disorders: The present invention relates to a method of treatment of sexual dysfunction e.g. female sexual disfunction by administering to a person in need of treatment an effective amount of gepirone as either a short-term or a long-term therapy.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070123537 - Quinazoline derivatives for the treatment of herpesviral infections: The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis... Agent: Brooks Kushman P.C.

20070123538 - Compositions comprising a combination of ccr5 and cxcr4 antagonists: e

20070123539 - Treatment of restenosis and stenosis with dasatinib: A method for treating or inhibiting artery obstructive disease, such as restenosis after angioplasty and stenting procedures and stenosis after coronary artery bypass surgery, in a subject by administering to the subject a therapeutically effective amount of dasatinib or a derivative thereof Also provided are drug-eluting medical devices, including stents,... Agent: Smith Hopen, Pa

20070123540 - Sexual desire enhancing medicaments comprising benzimidazolone derivatives: The invention relates to the use of benzimidazolone derivatives of formula (I) for the preparation of a medicament for the treatment of sexual desire disorders.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070123541 - Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the ergosterol biosynthesis: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I) (a) and a compound capable of inhibiting the ergosterol biosynthesis (b) in a (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic... Agent: Ostrolenk Faber Gerb & Soffen

20070123542 - Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds: and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods... Agent: Philip S. Johnson Johnson & Johnson

20070123543 - Novel compounds: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070123544 - Non-nucleotide compositions and method for treating pain: The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or... Agent: Howery LLP

20070123545 - Process for the preparation of aminoalcohol derivatives and their further conversion to (1r, 4s)-4(2-amino-6-chloro-5-formamido-4- pyrimidinyl)-amino-2-cyclopentenyl-1-methanol: e

20070123546 - 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either... Agent: Novartis Vaccines And Diagnostics Inc.

20070123547 - [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto: The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Townsend And Townsend And Crew, LLP

20070123548 - Pth agonists: R6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C1-8alkoxy, aryl, heteroaryl, halogen, NO2, CN, N3, SCF3, and CF3, or when R1 and/or R2 contains S(O)2NR5R6, CONR5R6, or C(S)NR5R6, then R5R6 together with... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070123549 - Pyrimidine compounds:

20070123550 - Crystalline rosuvastatin intermediate: Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20070123551 - Use of metabotropic glutamarate receptor 5 (mglur5) antagonists for the treatment of gastrointestinal disorders: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.... Agent: White & Case LLP Patent Department

20070123552 - Method of manufacturing of 7-ethyl-10-hydroxycamptotecin: The method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I characterized in that 7-ethyl-1,2,6,7-tetrahydrocampotothecin of formula IV is oxidized with an oxidizing agent selected from the group coprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in a solvent formed by a saturated aliphatic monocarboxylic... Agent: Notaro And Michalos

20070123553 - Aryl imidazoles and their use as anti-cancer agents: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods -of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-cancer agents; wherein: R1 is aryl, substituted aryl, heterocycle, substituted... Agent: Needle & Rosenberg, P.C.

20070123555 - Prevention and treatment of hearing disorders: Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. The methods employ nicergoline, MMDL or MDL as the sole active pharmaceutical agent or a combination of nicergoline, MMDL or MDL and another pharmaceutical agent, such as an antioxidant, a... Agent: Wilson Sonsini Goodrich & Rosati

20070123554 - Pyrazoloacrydone derivative-containing solution: m

20070123556 - Treatment with sigma receptor agonists post-stroke: A method of post-stroke treatment at delayed timepoints with sigma receptor agonists. Sigma receptors are promising targets for neuroprotection following ischemia. One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis. The sigma receptor agonist, DTG, was shown to depress... Agent: Smith Hopen, Pa

20070123557 - Soft anticholinergic esters: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the... Agent: Buchanan, Ingersoll & Rooney PC

20070123558 - Immune response modifier formulations containing oleic acid and methods: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: 3m Innovative Properties Company

20070123559 - Packaging for 1-(2-methylpropyl)-1h-imidazo[4,5-c] quinolin-4-amine-containing formulation: A packaged composition of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine dissolved in a fatty acid formulation and contained in a laminated packaging material having a contact layer that includes an acrylonitrile-methyl acrylate copolymer; an outer layer; and a moisture barrier layer disposed between the contact layer and outer layer.... Agent: Edwards Angell Palmer & Dodge LLP

20070123560 - Dehalogeno-compounds: 3-(1-Aminocycloalkyl)pyrrolidinyl-substituted-6-dehalodeno(hydrogen-substituted)quinolon carboxylic acid derivatives having specific substituents as represented by the following formula (I), its salts, and hydrates thereof exhibit a broad and potent antibacterial activity on gram-negative and gram-positive bacteria, in particular, resistant bacteria typified by gram-positive cocci, including MRSA, PRSP and VRE. Thus these compounds are usable as... Agent: Sughrue Mion, PLLC

20070123562 - Compositions and methods for treating middle-of-the-night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: Townsend And Townsend And Crew, LLP

20070123561 - Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors: Novel inhibitors of Rho-kinases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070123563 - Selective androgen receptor modulators and method of use thereof: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070123564 - Method for preparing phenyl acetic acid derivatives: i

20070123565 - Donepezil hydrochloride form vi: The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and its polymorph Form (VI).... Agent: Pharmaceutical Patent Attorneys, LLC

20070123566 - Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents: e

20070123567 - Prophylactic pretreatment with antioxidants: Methods, compositions, and uses for pre-treating patients who are susceptible to ischemia, including stroke, with nitroxides, in order to prevent or ameliorate the effects of stroke or other ischemic disease.... Agent: Knobbe Martens Olson & Bear LLP

20070123568 - Therapeutic methods using prostaglandin ep4 agonist components: Methods are provides directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastroentroeropathy and intestinal ischemia. Such administration results... Agent: Allergan, Inc.

20070123569 - Therapeutic methods using prostaglandin ep4 agonist components: Methods are provided directed to adminstering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastrophathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal... Agent: Allergan, Inc.

20070123570 - Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs: t

20070123571 - Use of a compound in the treatment of sleep disorders: There is disclosed the use of triprolidine, in combination with at least one further active pharmaceutical agent, for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of triprolidine, in combination with at least one further active pharmaceutical agent, as... Agent: Nixon & Vanderhye, PC

20070123572 - Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines: The present invention discloses a novel method for preparing 3-imidazol-1-yl-[1,2,4]thiadiazole derivatives, particularly to a method of preparing 5-halo-3-imidazol-1-yl-[1,2,4]thiadiazole, more particularly (3 -imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-dialkyl-amines, that afford a high yield of pure product.... Agent: International Patent Group Attn: Ms Lavern Hall

20070123573 - Process for the preparation of biologically active tetrahydrobenzthiazole derivative: The process comprises reacting 4-amino cyclohexanol of formula (III) or its acid addition salts with phthalic anhydride in presence of acid catalyst and their salts, in polar aprotic solvent or its mixture with organic solvent, capable of removing water azeotropically to give 4-(phthalimido)-cyclohexanol of formula (IV); oxidizing 4-(phthalimido)-cyclohexanol of formula... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070123574 - Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof: The present invention relates to methods for the preparation of benzoxazole sulfonamide compounds as well as novel intermediates for use in said method. More in particular the invention relates to methods for the preparation of 2-amino-benzoxazole sulfonamide compounds which make use of 2-mercapto-benzoxazole sulfonamide intermediates, more in particular methods employing... Agent: Philip S. Johnson Johnson & Johnson

20070123575 - Ep4 receptor antagonists: e

20070123576 - Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for in: The present invention relates to compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation. More specifically, it relates to compounds that induce neuron differentiation... Agent: Cantor Colburn, LLP

20070123577 - Inhibitor of protein modification products formation: [PROBLEMS] To provide a inhibitor of protein modification products formation capable of inhibiting of vitamin B6 deficiency disease as a side effect, especially a renal protective agent. [MEANS FOR SOLVING PROBLEMS] There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070123578 - Hexahydro-cycloheptapyrazole cannabinoid modulators: R

20070123579 - Process for preparing a dipeptidyl peptidase iv inhibitor and intermediates employed therein:

20070123580 - Combination of histone deacetylase inhibitors with chemotherapeutic agents: The invention relates to a combination which comprises (a) one or more chemotherapeutic agents and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases including pre-malignant lesions (e.g. colon polyps) and malignancies, both solid and undifferentiated or... Agent: Novartis Corporate Intellectual Property

20070123581 - Process for the synthesis of (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid compounds and application in the synthesis of perindopril: e

20070123582 - Crystalline form of a drug: Atrasentan Hydrochloride Crystalline Form 3, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070123583 - Method for treating atherosclerosis or restenosis using microtubule stabilizing agent: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or resenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or... Agent: Klarquist Sparkman, LLP

20070123584 - Method of treating premenstrual dysphoric disorder with escitalopram: The present invention relates to a method of treating the symptoms of premenstrual dysphoric disorder (PMDD) in a patient in need thereof by administering an effective amount of escitalopram or a pharmaceutically acceptable salt thereof.... Agent: Darby & Darby P.C.

20070123585 - Nitroglycerin therapy for those unable to metabolize nitroglycerin: Those in need of nitroglycerin (GTN) therapy who have polymorphism in the mtALDH gene, e.g., those of Asian descent for whom this polymorphism is common, and/or who are being treated with or ingesting or exposed to mtALDH inhibitor are treated with GTN in combination with agent which converts GTN to... Agent: Bacon & Thomas, PLLC

20070123586 - Nitroso derivatives of diphenylamine: o

20070123587 - Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors: The invention encompasses the novel compounds of Formula (I) and Formula (II), which are prodrugs that convert in vivo to diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. These prodrugs are far more soluble in aqueous media than the active agents into which they convert, in vivo. As such... Agent: Merck And Co., Inc

20070123588 - Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements: According to the present invention, acquired metabolic derangements or fatty acid disorders in humans that are manifested by a deficiency in at least one enzyme involved in fatty acid metabolism are treated with a five carbon or a fifteen carbon fatty acid source. Rapid nutritional supplementation can also be provided... Agent: Chalker Flores, LLP

20070123591 - Gabapentin analogues and process thereof: The present invention relates to compounds trans (E) and cis (Z) stereoisomers of 4-t-butyl gabapentin of formula (11) and (12) and a process for the preparation of the said stereoisomers.... Agent: Foley And Lardner LLP Suite 500

20070123589 - Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols: The invention relates to an improved method for producing chiral or enantiomer-enriched beta amino acids, -aldehydes, -ketones and gamma-amino alcohols, during which an allyl amine of formula (I), in which: R1 represents an alkyl radical, a cycloalkyl radical, an alkyl radical, a heterocycle radical or a condensed or bridged ring... Agent: Nixon & Vanderhye, PC

20070123590 - Process for the purification of gabapentin: A process for the preparation of gabapentin comprising the passage of a salt of the same through a ionic exchange resin of strong cationic type, the elution of the gabapentin which has fixed onto the column and the crystallization from organic solvent, characterized in that the resin is regenerated by... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070123592 - Terephthalamide peptidomimetic compounds and methods: The present invention relates to compounds and pharmaceutical compositions based upon terephthalamide which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding... Agent: Coleman Sudol Sapone, P.C.

20070123593 - Pharmaceutical composition comprising 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid: The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal... Agent: Novartis Corporate Intellectual Property

20070117741 - Defensin-inducing agents and related methods: This application provides, in part, novel polypeptides and nucleic acids that affect induction of defensins, and methods of making and using same.... Agent: Hahn Loeser & Parks, LLP

20070117742 - Methods and means for producing proteins with predetermined post-translational modifications: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining... Agent: Trask Britt

20070117743 - New antitumoral compounds: New analogues of kahalalide F are provided.... Agent: King & Spalding

20070117744 - Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents: The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a... Agent: Morrison & Foerster LLP

20070117745 - Cardio myopeptidin, the production and the use thereof: The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and... Agent: Wallenstein & Wagner, Ltd.

20070117751 - Compositions and methods for diagnosing and treating cancer: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070117753 - Conversion of apoptotic proteins: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with... Agent: Knobbe Martens Olson & Bear LLP

20070117757 - Copolymer-1 improvements in compositions of copolymers: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.... Agent: Kenyon & Kenyon LLP

20070117756 - Fvii or fviia gla domain variants: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use... Agent: Maxygen, Inc. Intellectual Property Department

20070117752 - Glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16,... Agent: Clark & Elbing LLP

20070117750 - Method for enhanced ocular drug penetration: Provided is a method for enhanced intraocular drug penetration that comprises the co-administration of ocular therapeutics with agents that increases the permeability of ocular and periocular vessels and ocular epithelial barriers. Due to its unique and novel concept and additive nature, the method of the present invention can be used... Agent: Edward Langer C/o Shiboleth

20070117755 - Methods for blocking tnf-alpha activity in mammals with trimeric soluble tnf receptors: This invention relates to a general methodology for efficient creation of trimeric soluble receptors for therapeutic applications. The process involves gene fusion between a soluble receptor with a ligand binding domain and a trimerization tag from the C-propeptide domain of pro-collagen, which is capable of self-assembly into a covalently linked... Agent: Lambert & Associates, P.l.l.c.

20070117754 - Nectin polypeptides, polynucleotides, methods of making and use thereof: This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and angiogenesis, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function,... Agent: Immunex Corporation Law Department

20070117748 - Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.... Agent: Sheridan Ross PC

20070117749 - Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ΔMrsA host cell an expression vector encoding said variant, and recovering said variant from the cell... Agent: Nixon & Vanderhye, PC

20070117747 - Treating disorders of the nervous system: A polypeptide may include an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 42, wherein a residue at position 94 of the polypeptide is an amino acid other than threonine or wherein a residue at position 82 of the polypeptide... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070117746 - Treatment of viral infections: The present invention concerns polypeptides derived from a tandem repeat of apoE141-149 and their uses as medicaments. The peptides may comprise the tandem repeat, and truncations thereof, for which at least one Leucine (L) is replaced by an amino acid with a side chain comprising at least 4 carbon atoms... Agent: Davis Wright Tremaine LLP

20070117758 - Therapeutic agents and methods of use thereof for the modulation of angiogenesis: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to... Agent: Lahive & Cockfield, LLP

20070117759 - Blister pack and solid dosage form therefor: The present invention relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, and to say solid dosage form. In one embodiment it specifically relates to a blister pack for pharmaceutical use comprising blisters containing a solid... Agent: Foley And Lardner LLP Suite 500

20070117760 - Dna minor groove binding compounds: There is provided an oligopeptide compound comprising: (a) at least one nitrogen-containing basic group attached to at least one end of the oligopeptide; and (b) two or more heterocyclic monomers, at least one of which is substituted in the heterocyclic part by a branched, cyclic or part cyclic C3-5 alkyl... Agent: Fish & Richardson PC

20070117761 - Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof: e

20070117762 - Use of an alkanoyl l-carnitine for the treatment of the erectile dysfunction: Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin E1, pentolamine and papaverine.... Agent: Nixon & Vanderhye, PC

20070117763 - Compositions and methods for treatment and prevention of metabolic syndrome and its associated conditions with combinations of flavonoids, liminoids and tocotrienols: The present invention is directed to compositions and methods for the treatment and/or prevention of metabolic syndrome and its associated conditions, such as insulin resistance, which involve using a combination composition of limonoids, flavonoids and tocotrienols.... Agent: Davidson, Davidson & Kappel, LLC

20070117764 - Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials: Highly compatible or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an antibacterial such as sulfasalazin, ciprofloxacin, ofloxacin, erythromycin or gentamycin, optionally with a further pharmaceutically active agent, especially a retinoid, are provided, which are useful in particular in the treatment of diseases involving bacterial... Agent: Novartis Corporate Intellectual Property

20070117765 - Nicotinoyl riboside compositions and methods of use: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention... Agent: Medlen & Carroll, LLP

20070117768 - Anti-apoptotically active apatamers: The invention relates to anti-apoptotically active apatamers. The invention describes possible therapeutic and diagnostic applications for, among other things, treating arteriosclerosis, promoting the healing of wounds, treating AIDS, cancer, Alzheimer's disease, systemic lupus erythematosus as well a rheumatoid arthritis and other chronic inflammatory diseases.... Agent: Marshall, Gerstein & Borun LLP

20070117770 - Human ribosomal dna (rdna) and ribosomal rna (rrna) nucleic acids and uses thereof: Provided herein are isolated nucleic acids that comprise a human rRNA or rDNA subsequence and related compositions and methods of use.... Agent: Morrison & Foerster LLP

20070117772 - Methods for slowing familial als disease progression: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous... Agent: Knobbe, Martens, Olson & Bear, LLP

20070117769 - Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase: The present invention relates to a method of modifying expression of cell cycle or cell signaling proteins. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in the nuclear or cellular concentration of biliverdin reductase, or... Agent: Nixon Peabody LLP - Patent Group

20070117767 - Sirna molecules and method of suppressing gene expression with the use of the same: The present invention relates to a double-stranded RNA molecule improved to control the gene expression suppressing effect of an siRNA. The double-stranded RNA molecule of the present invention is designed such that, in a double-stranded RNA molecule capable of suppressing the expression of a target gene in a cell by... Agent: Ladas & Parry

20070117774 - Somatic transgene immunization and related methods: The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin... Agent: Needle & Rosenberg, P.C.

20070117773 - Telomerase-inhibiting ena oligonucleotide: A telomerase-inhibiting ENA oligonucleotide compound represented by a formula: E1-B1-B2-B3-B4-E2 (I), wherein E1 represents a group represented by the formula R1-; E2 represents a group represented by the formula -B7-R2; B4, B5, and B8 are identical or different, and each represents Tp; B1, B2, B3, and B12 are identical or... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070117771 - Vglut-specific dsrna compounds: VGLUT-specific dsRNAs capable of triggering the phenomenon of RNA interference, host cells containing theses dsRNAs, and pharmaceutical compositions containing these dsRNAs, in particular for the treatment of pain and other diseases associated with VGLUT family members.... Agent: Crowell & Moring LLP Intellectual Property Group

20070117766 - Vigilant cells: The invention concerns a system for modulating tissue physiology, for example, to prevent or reverse tissue damage caused by disease. The system utilizes vigilant cells that include stable vectors containing a gene switch/biosensor and a gene amplification system. The vectors allow expression of a transgene (such as a cardioprotective gene)... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070117775 - Compositions and methods for treating inflammatory disorders: The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and an anti-inflammatory agent.... Agent: Dechert LLP

20070117776 - Low dose therapy of dna methylation inhibitors: Methods are provided for treating patients with hematological disorders such as acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and the myelodysplastic syndromes (MDS). By administering a DNA methylation inhibitor to the patients following unique dosing regimens, the diseases can be efficaciously treated with reduced toxic side effects.... Agent: Wilson Sonsini Goodrich & Rosati

20070117778 - Beta glycolipids as immuno-modulators: The present invention relates to a process for the modulation of the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells, in a subject suffering from an immune related disorder. The process of the invention comprises the step of increasing the intracellular, extra-cellular or serum level of a naturally occurring β-glycolipid... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070117777 - Composition containing beta-glucan for prevention and treatment of osteoporosis: The present invention relates to a composition containing beta-glucan as an effective ingredient for prevention and treatment of osteoporosis. The above captioned beta-glucan is preferably the beta-1.3/1.6 glucan having a lactic acid as a substituent and this beta-1.3/1.6 glucan is preferably produced from Auerobasidium pullulans SM2001(KCCM 10307).... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070117779 - Use of lipid conjugates in the treatment of disease: The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof.... Agent: Pearl Cohen Zedek Latzer, LLP

20070117780 - Process to prepare eplerenone: e

20070117781 - Pharmaceutical formulation with improved stability: An oral formulation which includes an intragranular phase comprising a bisphosphonic acid derivative and at least one carbohydrate alcohol, together with an aqueous binder. A process of preparing the same and a therapeutic method employing such a formulation in the treatment of various skeletal diseases, such as systemic bone diseases... Agent: Conley Rose, P.C.

20070117782 - Inhibitors of epoxide hydrolases for the treatment of inflammation: wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur... Agent: Townsend And Townsend And Crew, LLP

20070117783 - Aqueous suspensions of ciclesonide for nebulisation: This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases.... Agent: Nath & Associates PLLC

20070117784 - Treatment of hyperproliferative diseases with anthraquinones: The invention relates to anthraquinone compounds having activity for treating hyperproliferative disorders. Further, the invention relates to methods of using the compounds, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070117785 - Substituted pyrazoles and methods of treatment with substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.... Agent: Philip S. Johnson Johnson & Johnson

20070117786 - Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives: b

20070117787 - Benzoxazepine compounds, their production and use: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of... Agent: Edwards & Angell, LLP

20070117788 - Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases: The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070117789 - Method of treatment: e

20070117790 - Nonpeptide substituted spirobenzoazepines as vasopressin antagonists: wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula... Agent: Philip S. Johnson Johnson & Johnson

20070117791 - Bicyclic compounds: wherein R1, R2, R3, R4 and R5, X, X′, Y and Y′ are as defined in the description and claims, processes for their preparation, pharmaceutical compositions containing said derivatives and their use for the preparation of medicaments useful for the prevention and treatment of diseases in which selective inhibition of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070117792 - Pharmaceutical compositions for suppressing b-amyloid production: To provide pharmaceutical compositions for suppressing β-amyloid production on the basis of the cyclin-dependent kinase inhibitory activity. When a substance having a cyclin-dependent kinase inhibitory activity was allowed to contact with nerve cells, the β-amyloid production was suppressed.... Agent: Sughrue-265550

20070117793 - Compounds which inhibit beta-secretase activity and methods of use: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20070117794 - Methods of treatment using oxytocin receptor agonists: Methods for treating and preventing anxiety, anxiety-related disorders, schizophrenia and schizophrenia-related disorders are described herein wherein said methods comprise the administration of oxytocin receptor agonists.... Agent: Wyeth Patent Law Group

20070117795 - Methods and compositions of novel triazine compounds: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that... Agent: Dr. Reddy's Laboratories, Inc.